CA2195665A1 - Pharmaceutical compositions comprising a chimaeric tnf binding protein - Google Patents

Pharmaceutical compositions comprising a chimaeric tnf binding protein

Info

Publication number
CA2195665A1
CA2195665A1 CA002195665A CA2195665A CA2195665A1 CA 2195665 A1 CA2195665 A1 CA 2195665A1 CA 002195665 A CA002195665 A CA 002195665A CA 2195665 A CA2195665 A CA 2195665A CA 2195665 A1 CA2195665 A1 CA 2195665A1
Authority
CA
Canada
Prior art keywords
tnf
binding protein
human
tnf binding
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002195665A
Other languages
English (en)
French (fr)
Inventor
Robert Frederick Geoffrey Booth
Werner Lesslauer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2195665A1 publication Critical patent/CA2195665A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002195665A 1994-07-22 1995-07-15 Pharmaceutical compositions comprising a chimaeric tnf binding protein Abandoned CA2195665A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94111455 1994-07-22
EP94111455.5 1994-07-22

Publications (1)

Publication Number Publication Date
CA2195665A1 true CA2195665A1 (en) 1996-02-08

Family

ID=8216138

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002195665A Abandoned CA2195665A1 (en) 1994-07-22 1995-07-15 Pharmaceutical compositions comprising a chimaeric tnf binding protein

Country Status (11)

Country Link
EP (1) EP0772449A1 (de)
JP (1) JPH09508140A (de)
AU (1) AU3111995A (de)
BR (1) BR9508419A (de)
CA (1) CA2195665A1 (de)
CZ (1) CZ283219B6 (de)
FI (1) FI970247A (de)
HU (1) HUT76666A (de)
NO (1) NO970264L (de)
PL (1) PL318501A1 (de)
WO (1) WO1996003141A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000033244A2 (en) 1998-11-27 2000-06-08 Synaptics (Uk) Limited Position sensor
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6471956B1 (en) 1994-08-17 2002-10-29 The Rockefeller University Ob polypeptides, modified forms and compositions thereto
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
EP0910413A2 (de) * 1996-05-08 1999-04-28 F. Hoffmann-La Roche Ag Behandlung von asthma mit tnfr-ig
TW555765B (en) * 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
US7070771B1 (en) 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
WO1998025967A1 (en) * 1996-12-12 1998-06-18 Genentech, Inc. Hvem polypeptides and uses thereof
MXPA03007563A (es) 2001-02-23 2003-12-11 Immunex Corp Recuperacion incrementada de proteinas activas.
WO2003011323A1 (en) * 2001-07-30 2003-02-13 Genset S.A. Agonists and antagonists of contabix for use in the treatment of metabolic disorders
US7786282B2 (en) 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
US7674453B2 (en) 2002-02-06 2010-03-09 Ares Trading Sa Tumor necrosis factor combined with interferon in demyelinating diseases
AU2005299716B2 (en) 2004-10-22 2012-09-06 Amgen Inc. Methods for refolding of recombinant antibodies
US11111284B2 (en) 2014-08-21 2021-09-07 The General Hospital Corporation Tumor necrosis factor superfamily and TNF-like ligand muteins and methods of preparing

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL98078A0 (en) * 1991-05-07 1992-06-21 Yeda Res & Dev Pharmaceutical compositions comprising an anticytokyne
EP0417563B1 (de) * 1989-09-12 2000-07-05 F. Hoffmann-La Roche Ag TNF-bindende Proteine
GB9015908D0 (en) * 1990-07-19 1990-09-05 Celltech Ltd Multivalent immunoglobulin
CA2123593C (en) * 1992-09-15 2000-03-14 Craig A. Smith Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
AU682156B2 (en) * 1992-10-15 1997-09-25 Dana-Farber Cancer Institute, Inc. Treatment of insulin resistance in obesity linked type II diabetes using antagonists to TNF-alpha function

Also Published As

Publication number Publication date
PL318501A1 (en) 1997-06-23
JPH09508140A (ja) 1997-08-19
HUT76666A (en) 1997-10-28
CZ283219B6 (cs) 1998-02-18
AU3111995A (en) 1996-02-22
FI970247A0 (fi) 1997-01-21
NO970264D0 (no) 1997-01-21
BR9508419A (pt) 1997-11-18
FI970247A (fi) 1997-01-21
EP0772449A1 (de) 1997-05-14
NO970264L (no) 1997-03-24
WO1996003141A1 (en) 1996-02-08
CZ19397A3 (en) 1997-06-11

Similar Documents

Publication Publication Date Title
CA2195665A1 (en) Pharmaceutical compositions comprising a chimaeric tnf binding protein
JP6526872B2 (ja) 関節リウマチの治療のための可溶性ｃｄ２４の使用方法
DE69633624T2 (de) Lösliche lymphotoxin-beta -rezeptoren, antikörper gegen den lymphotoxinrezeptor und ligand-antikörper als therapeutische reagenzien in der behandlung von immunkrankheiten
DE69533331T2 (de) Liganden zur induktion der antigen-spezifischen apoptose in t-zellen
KR20070047327A (ko) 항-ｃｄ154 항체
WO2000012130A1 (en) Rp105 agonists and antagonists
EP2497498A1 (de) Therapeutischer wirkstoff für autoimmunerkrankungen oder allergien sowie verfahren zum screening nach dem therapeutischen wirkstoff
EP0936923A1 (de) Unterdrückung vom tnf und il-12 in therapie
DE69736597T2 (de) Gdnf rezeptor
US5676940A (en) Method of reducing immunoglobulin E responses
ES2210551T3 (es) Neuritina, un neurogeno.
DE69931944T2 (de) Umkehr des viral-induzierten systemischen schocks und des atemnotsyndroms durch blockierung des lymphotoxin-beta- aktivierungsweges
JP4452312B2 (ja) Ｔ細胞抗原受容体ペプチド
KR100622960B1 (ko) 림프독소（ｌｔ）경로 저해제를 사용한 여포 림프종의 치료 방법
EP1223958A2 (de) Präparationsmethoden und verbindungen von peptidkonstruktionen die sich zur behandlung von autoimmun- bzw. transplantationsbedingten "host versus graft" pathogenesen eignen
JPH06298662A (ja) 自己免疫疾患の予防治療剤
JP2002505576A (ja) 神経栄養因子レセプター
CA2456247C (en) Use of il-18 inhibitors in hypersensitivity disorders
US5861164A (en) Vaccination against diseases resulting from pathogenic responses by specific T cell populations
DE69637429T2 (de) Gene, die für lymphocyte spezifischen interferon-regulationsfaktor (lsirf) polypeptide kodiert
AU2002331376A1 (en) Use of IL-18 inhibitors in hypersensitivity disorders
EP1598370A2 (de) Präparationsverfahren und Verbindungen von Peptidkonstrukten die sich zur Behandlung von autoimmun- bzw. transplantationsbedingten Pathogenesen eignen

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued